Supplementary materials:

Table S1. Calibration standard preparation.

	Blank	**Std 1**	**Std 2**	**Std 3**	**Std 4**	**Std 5**	**Std 6**	
CBD	**0**	**0.50**	**2.0**	**5.0**	**10**	**25**	**50**	**ng/mL**
7-COOH-CBD	**0**	**5.0**	**20**	**50**	**100**	**250**	**500**	**ng/mL**
Plasma	500	450	480	450	480	450	450	µL
SF1	-	-	-	-	-	-	50	µL
SF2	-	-	-	-	20	50	-	µL
SF3	-	-	20	50	-	-	-	µL
SF4	-	50	-	-	-	-	-	µL

Table S2. Validation standard preparation.

	Val 1	**Val 2**	**Val 3**	**Val 4**	
CBD	**0.50**	**1.5**	**15**	**50**	**ng/mL**
7-COOH-CBD	**5.0**	**15**	**150**	**500**	**ng/mL**
Plasma	450	485	470	450	µL
SF1	-	-	-	50	µL
SF2	-	-	30	-	µL
SF3	-	15			µL
SF4	50	-	-	-	µL

Table S3. Quality control (QC) sample preparation.

	QC1	**QC2**	**QC3**	
CBD	**1.5**	**15**	**50**	**ng/mL**
7-COOH-CBD	**15**	**150**	**500**	**ng/mL**
Plasma	485	470	450	µL
SF1	-	-	50	µL
SF2	-	30	-	µL
SF3	15	-	-	µL

Table S4. Linearity.

	Linear regression model	r^2	r	Residual sum of square
CBD	y = 0.004757 + 1.006x	0.9987	0.9994	30.63
7-COOH-CBD	y = 1.505 + 0.9717 x	0.9985	0.9992	3509



Figure S1. *In vitro* drug release of CBD within the CBD: HP-β-CD spray-dried complex in sink conditions; medium at pH 6.8 + 1% SLS; 37 °C, Withdrawals at 1, 2 and 5 minutes were filtered through PTFE 0.2 μm prior to HPLC analysis via validated method (n = 2).